CLASS II Drug recall · Reported 4 Sep 2024 · FDA Enforcement Report

Cefixime for Oral Suspension USP, 100 mg recalled

Lupin Pharmaceuticals is recalling Cefixime for Oral Suspension USP, 100 mg, distributed nationwide in the US. The recall was initiated on 21 Aug 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: F201517, Exp 11/30/2024
NDC68180-405, 68180-407, 68180-416, 68180-423
UPC0368180423089, 0368180407034, 0368180416081, 0368180416111
Quantity recalled4554 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0648-2024
FDA event ID
95193
Recalling firm
Lupin Pharmaceuticals, Baltimore, MD
Manufacturer
Lupin Pharmaceuticals, Inc.
Classification
Class II
Status
Terminated
Recall initiated
21 Aug 2024
FDA classified
26 Aug 2024
Reported
4 Sep 2024
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

21 Aug 2024Recall initiated by company
26 Aug 2024Classified by FDA+5 days
4 Sep 2024Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Cefixime for Oral Suspension USP, 100 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA, NDC 68180-405-01

Where it was distributed

USA nationwide.

Nationwide

Questions about this recall

Is Cefixime for Oral Suspension USP, 100 mg recalled?

Yes. Lupin Pharmaceuticals recalled Cefixime for Oral Suspension USP, 100 mg on 21 Aug 2024. The recall is Class II and its status is Terminated. Recall number D-0648-2024.

Why was it recalled?

Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.

Which lots are affected?

Lot #: F201517, Exp 11/30/2024

Where was it sold?

USA nationwide.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Lupin Pharmaceuticals

All 123
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIClobetasol Propionate Cream USP, 05% tube recalledClobetasol PropionateLupin PharmaceuticalsOtherNationwide
DrugCLASS IIprednisoLONE Acetate Ophthalmic Suspension recalledPrednisolone AcetateLupin PharmaceuticalsSterilityNationwide
DrugCLASS IIGlucagon Emergency Kit for Low Blood Sugar, Glucagon recalledGlucagonLupin PharmaceuticalsPotency & AssayNationwide
DrugCLASS IILiraglutide Injection, 18 mg/ (6 mg/mL) recalledLiraglutideLupin PharmaceuticalsParticulate MatterNationwide
DrugCLASS IISertraline Hydrochloride Tablets USP, 100 mg recalledSertraline HydrochlorideLupin PharmaceuticalsPackaging DefectsNationwide

Other Cefixime recalls

All 7